Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
83.85
-2.83 (-3.26%)
At close: Apr 28, 2026, 4:00 PM EDT
83.83
-0.02 (-0.03%)
After-hours: Apr 28, 2026, 7:20 PM EDT
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 25 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 107.72, with a low estimate of 52 and a high estimate of 140. The average target predicts an increase of 28.47% from the current stock price of 83.85.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 16, 2026.
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock from 26 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 10 | 12 | 12 | 12 | 14 | 14 |
| Buy | 9 | 11 | 11 | 12 | 11 | 11 |
| Hold | 0 | 0 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 23 | 24 | 25 | 26 | 26 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $122 → $110 | Strong Buy | Initiates | $122 → $110 | +31.19% | Mar 16, 2026 |
| UBS | UBS | Strong Buy Maintains $90 → $128 | Strong Buy | Maintains | $90 → $128 | +52.65% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $110 → $120 | Strong Buy | Maintains | $110 → $120 | +43.11% | Mar 2, 2026 |
| Stephens & Co. | Stephens & Co. | Buy Maintains $95 → $100 | Buy | Maintains | $95 → $100 | +19.26% | Mar 2, 2026 |
| BTIG | BTIG | Strong Buy Maintains $138 → $134 | Strong Buy | Maintains | $138 → $134 | +59.81% | Feb 26, 2026 |
Financial Forecast
Revenue This Year
43.37M
from 39.21M
Increased by 10.61%
Revenue Next Year
46.92M
from 43.37M
Increased by 8.17%
EPS This Year
-3.86
from -3.69
EPS Next Year
-4.06
from -3.86
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 102.9M | 102.9M | ||||||
| Avg | 43.4M | 46.9M | ||||||
| Low | 9.8M | -12.7M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 162.5% | 137.3% | ||||||
| Avg | 10.6% | 8.2% | ||||||
| Low | -75.0% | - |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | -3.11 | -0.67 | ||||||
| Avg | -3.86 | -4.06 | ||||||
| Low | -4.36 | -6.03 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | ||||||
| Avg | - | - | ||||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.